Gwenny M. Verstappen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gwenny M. Verstappen has a total of 175 co-authors. Here are the top co-authors by number of shared publications:
Hendrika Bootsma
Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands
13 shared publications- Frans G. M. Kroese
Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands
9 shared publications - Hendrika Bootsma
Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
9 shared publications Arjan Vissink
University of Groningen, University Medical Center Groningen Groningen The Netherlands
7 shared publications- Liseth de Wolff
Rheumatology and Clinical Immunology, University of Groningen, University Medical Centre Groningen, Groningen, Groningen, The Netherlands
7 shared publications Frans G. M. Kroese
Department of Rheumatology and Clinical Immunology University of Groningen University Medical Center Groningen Groningen The Netherlands
6 shared publications
Latest Publications
- 2 July 2026
- Published by Elsevier in The Lancet Rheumatology
- Vol. 8 (8) , e589-e591
Interferon-α in Sjögren's disease: cause or consequence?
- 2 July 2026
- Published by Elsevier in The Lancet Rheumatology
- Vol. 8 (8) , e589-e591
Interferon-α in Sjögren's disease: cause or consequence?
- Open Access
- 16 April 2026
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 85 (7) , 1341-1350
Efgartigimod in Sjögren’s disease: a phase 2, randomised, placebo-controlled, parallel-group, double-blinded, proof-of-concept study (RHO)
- 16 April 2026
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 85 (7) , 1341-1350
Open AccessEfgartigimod in Sjögren’s disease: a phase 2, randomised, placebo-controlled, parallel-group, double-blinded, proof-of-concept study (RHO)
- Open Access
- 17 February 2026
- Published by Elsevier in Current Opinion in Immunology
- Vol. 99, 102739
T cells in Sjögren’s disease: update on their role in salivary gland pathogenesis and treatment
- 17 February 2026
- Published by Elsevier in Current Opinion in Immunology
- Vol. 99, 102739
Open AccessT cells in Sjögren’s disease: update on their role in salivary gland pathogenesis and treatment
- Open Access
Functional immune profiling reveals CD4 + T cell dysregulation associated with coeliac disease
T cells integrate signals from antigen and co-stimulatory receptors to calibrate the strength and quality of their responses. This signal integration is influenced by genetic background, which can modulate thresholds for immune tolerance and strength of responses to threat. Celiac disease (CeD) is an autoimmune disorder driven by well-defined genetic risk and characterised by immune dysregulation in response to dietary gluten. However, whether sensitivity or response differences in naive T cell programming contributes to disease susceptibility is not known. To investigate such variation, we developed a sensitive quantitative platform, ‘the momentum assay’, which combines standardised, T cell activation with subsequent stimulus withdrawal, enabling measurement of T cell proliferation and survival over time. This assay is integrated with the Cyton2 mathematical model to infer underlying cellular timer programs from population-level dynamics. We applied this method to assess whether naïve T cells from individuals with celiac disease (CeD) exhibited altered responses compared to healthy donors (HDs). We found that CD4 + but not CD8 + T cells from CeD patients showed a hypo-proliferative response following stimulation, associated with impaired secretion of the proliferative and pro-survival cytokine IL-2. Moreover, surface expression of early activation marker, CD69 remained elevated for longer on CD4 + T cells from CeD donors after stimulus withdrawal, suggesting prolonged activation and subtle alterations in regulatory feedback mechanisms. These findings reveal previously unrecognised quantitative alterations in naïve T cell programming in CeD and underscore the utility of model-based analytical frameworks for detecting subtle functional perturbations in complex immune-mediated diseases.
Open AccessFunctional immune profiling reveals CD4 + T cell dysregulation associated with coeliac disease
T cells integrate signals from antigen and co-stimulatory receptors to calibrate the strength and quality of their responses. This signal integration is influenced by genetic background, which can modulate thresholds for immune tolerance and strength of responses to threat. Celiac disease (CeD) is an autoimmune disorder driven by well-defined genetic risk and characterised by immune dysregulation in response to dietary gluten. However, whether sensitivity or response differences in naive T cell programming contributes to disease susceptibility is not known. To investigate such variation, we developed a sensitive quantitative platform, ‘the momentum assay’, which combines standardised, T cell activation with subsequent stimulus withdrawal, enabling measurement of T cell proliferation and survival over time. This assay is integrated with the Cyton2 mathematical model to infer underlying cellular timer programs from population-level dynamics. We applied this method to assess whether naïve T cells from individuals with celiac disease (CeD) exhibited altered responses compared to healthy donors (HDs). We found that CD4 + but not CD8 + T cells from CeD patients showed a hypo-proliferative response following stimulation, associated with impaired secretion of the proliferative and pro-survival cytokine IL-2. Moreover, surface expression of early activation marker, CD69 remained elevated for longer on CD4 + T cells from CeD donors after stimulus withdrawal, suggesting prolonged activation and subtle alterations in regulatory feedback mechanisms. These findings reveal previously unrecognised quantitative alterations in naïve T cell programming in CeD and underscore the utility of model-based analytical frameworks for detecting subtle functional perturbations in complex immune-mediated diseases.
- Open Access
- 22 January 2025
- Published by Elsevier in Journal of Translational Autoimmunity
- Vol. 10, 100270
Aberrant B cell receptor signaling responses in circulating double-negative 2 B cells from radiographic axial spondyloarthritis patients
- 22 January 2025
- Published by Elsevier in Journal of Translational Autoimmunity
- Vol. 10, 100270
Open AccessAberrant B cell receptor signaling responses in circulating double-negative 2 B cells from radiographic axial spondyloarthritis patients
- Open Access
- 20 December 2024
- Published by Wiley in European Journal of Immunology
- Vol. 55 (2) , e202451398
B Cell Receptor Repertoire Analysis of the CD21lo B Cell Compartment in Healthy Individuals, Patients With Sjögren's Disease, and Patients With Radiographic Axial Spondyloarthritis
B cells with low or absent expression of CD21 (CD21lo B cells) gained attention due to their expansion in the peripheral blood of patients with immune‐mediated, rheumatic diseases. This is not only observed in typical autoimmune diseases like systemic lupus erythematosus and Sjögren's disease (SjD) but also in radiographic axial spondyloarthritis (r‐axSpA), which is considered an autoinflammatory disease. To gain more insight into the origins of the heterogeneous CD21lo B‐cell population, and its relation to the plasmablast (PB) compartment, we profiled the B‐cell‐receptor (BCR) repertoire in CD27− and CD27+ fractions of CD21lo B cells and early PBs using next‐generation sequencing. Populations were sorted from peripheral blood of healthy individuals, SjD patients, and r‐axSpA patients (n = 10 for each group). In healthy individuals and both patient groups, our findings indicate that CD27−CD21lo B cells, which exhibit few mutations in their BCR, may develop into CD27+CD21lo B cells and PBs, both marked by considerably more mutations. Given the known expansion of circulating CD27−CD21lo B cells in SjD and r‐axSpA patients and clonal relationships with both CD27+CD21lo B cells and early PBs, these cells might actively contribute to (pathological) immune responses in rheumatic diseases with autoimmune and/or autoinflammatory characteristics.
- 20 December 2024
- Published by Wiley in European Journal of Immunology
- Vol. 55 (2) , e202451398
Open AccessB Cell Receptor Repertoire Analysis of the CD21lo B Cell Compartment in Healthy Individuals, Patients With Sjögren's Disease, and Patients With Radiographic Axial Spondyloarthritis
B cells with low or absent expression of CD21 (CD21lo B cells) gained attention due to their expansion in the peripheral blood of patients with immune‐mediated, rheumatic diseases. This is not only observed in typical autoimmune diseases like systemic lupus erythematosus and Sjögren's disease (SjD) but also in radiographic axial spondyloarthritis (r‐axSpA), which is considered an autoinflammatory disease. To gain more insight into the origins of the heterogeneous CD21lo B‐cell population, and its relation to the plasmablast (PB) compartment, we profiled the B‐cell‐receptor (BCR) repertoire in CD27− and CD27+ fractions of CD21lo B cells and early PBs using next‐generation sequencing. Populations were sorted from peripheral blood of healthy individuals, SjD patients, and r‐axSpA patients (n = 10 for each group). In healthy individuals and both patient groups, our findings indicate that CD27−CD21lo B cells, which exhibit few mutations in their BCR, may develop into CD27+CD21lo B cells and PBs, both marked by considerably more mutations. Given the known expansion of circulating CD27−CD21lo B cells in SjD and r‐axSpA patients and clonal relationships with both CD27+CD21lo B cells and early PBs, these cells might actively contribute to (pathological) immune responses in rheumatic diseases with autoimmune and/or autoinflammatory characteristics.
- 23 September 2024
- Published by Clinical and Experimental Rheumatology in Clinical and Experimental Rheumatology
- Vol. 42 (12) , 2319-2321
Highlights from the 16th International Symposium for Sjögren's Disease
- 23 September 2024
- Published by Clinical and Experimental Rheumatology in Clinical and Experimental Rheumatology
- Vol. 42 (12) , 2319-2321
Highlights from the 16th International Symposium for Sjögren's Disease
- Open Access
More severe parotid gland histopathology in paediatric-onset than in adult-onset Sjögren’s disease
Objectives: The aim of this study was to assess the histopathological features of the parotid glands in patients with paediatric-onset Sjögren’s disease (pedSjD) in comparison to patients with adult-onset Sjögren’s disease (adSjD). Methods: This study was performed in Groningen, the Netherlands. Patients with pedSjD from a diagnostic paediatric cohort (n=19), patients with adSjD from a diagnostic adult cohort (n=32) and patients with adSjD who participated in a clinical trial (n=42) with a baseline parotid gland biopsy were included. Parotid gland biopsies were analysed after (immuno)histological staining for SjD-related histopathological markers and compared between groups. Results: All characteristic histopathological features of adSjD were also observed in pedSjD. There were no significant differences in lymphoepithelial lesions or immunoglobulin A (IgA)/IgG plasma cell shift between the pedSjD and the adSjD cohorts. However, compared with the diagnostic adSjD cohort (with comparable total EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) scores), pedSjD showed more severe lymphocytic infiltration as reflected by a higher focus score (p=0.003), a higher relative surface area of CD45+ infiltrate (p=0.041), higher numbers of B and T lymphocytes/mm2 (p=0.004 and p=0.029, respectively), a higher B/T lymphocyte ratio (p=0.013), higher numbers of CD21+ follicular dendritic cell networks/mm2 (p=0.029) and germinal centres (GC)/mm2 (p=0.002). Compared with the trial adSjD cohort, with significant higher total ESSDAI scores (p=0.001), only the B/T lymphocyte ratio and numbers of GC/mm2 were significantly higher in the pedSjD cohort (p=0.023 and p=0.018, respectively). Conclusion: Patients with pedSjD exhibit more pronounced histopathological features compared with patients with adSjD at diagnosis. Notably, the histopathology of patients with pedSjD aligns more closely with that observed in an adSjD clinical trial cohort, with even stronger B lymphocyte involvement.
Open AccessMore severe parotid gland histopathology in paediatric-onset than in adult-onset Sjögren’s disease
Objectives: The aim of this study was to assess the histopathological features of the parotid glands in patients with paediatric-onset Sjögren’s disease (pedSjD) in comparison to patients with adult-onset Sjögren’s disease (adSjD). Methods: This study was performed in Groningen, the Netherlands. Patients with pedSjD from a diagnostic paediatric cohort (n=19), patients with adSjD from a diagnostic adult cohort (n=32) and patients with adSjD who participated in a clinical trial (n=42) with a baseline parotid gland biopsy were included. Parotid gland biopsies were analysed after (immuno)histological staining for SjD-related histopathological markers and compared between groups. Results: All characteristic histopathological features of adSjD were also observed in pedSjD. There were no significant differences in lymphoepithelial lesions or immunoglobulin A (IgA)/IgG plasma cell shift between the pedSjD and the adSjD cohorts. However, compared with the diagnostic adSjD cohort (with comparable total EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) scores), pedSjD showed more severe lymphocytic infiltration as reflected by a higher focus score (p=0.003), a higher relative surface area of CD45+ infiltrate (p=0.041), higher numbers of B and T lymphocytes/mm2 (p=0.004 and p=0.029, respectively), a higher B/T lymphocyte ratio (p=0.013), higher numbers of CD21+ follicular dendritic cell networks/mm2 (p=0.029) and germinal centres (GC)/mm2 (p=0.002). Compared with the trial adSjD cohort, with significant higher total ESSDAI scores (p=0.001), only the B/T lymphocyte ratio and numbers of GC/mm2 were significantly higher in the pedSjD cohort (p=0.023 and p=0.018, respectively). Conclusion: Patients with pedSjD exhibit more pronounced histopathological features compared with patients with adSjD at diagnosis. Notably, the histopathology of patients with pedSjD aligns more closely with that observed in an adSjD clinical trial cohort, with even stronger B lymphocyte involvement.
- Open Access
Inflammatory Bowel Disease in patients with Primary Sclerosing Cholangitis: a distinct form of colitis
Background and aims Primary sclerosing cholangitis (PSC) is an inflammatory disorder of the bile ducts, often accompanied by inflammatory bowel disease (PSC-IBD). Substantial differences in clinical presentation are observed between PSC-IBD and ulcerative colitis (UC). In this study we aim to find distinct pathomechanisms for PSC-IBD using single-cell mRNA sequencing. Methods Forty-seven colonic mucosal biopsies of PSC-IBD (n=24), UC (n=18) (where possible matched inflamed (I) non-inflamed (NI)), and non-IBD subjects (n=5) were collected and dissociated. Library preparation and processing for sequencing was followed by differential abundance, differential expression, and cell-cell-interaction analyses. Stainings for DUOX2 and HLA-DR were applied on tissue sections. Results In total, 71,798 cells comprised 54 distinct cell types, including a new cell type: the DUOX2+ enterocyte, mainly present in inflamed colon and acting as antigen presenting cells (HLA-DR+). Stem cells exhibited increased abundances in PSC-NI but not in UC-NI. Additionally, we found distinct gene expression profiles in PSC and UC which were related to inflammation: while mainly inflammatory monocytes were activated in PSC inflammation, and inflammatory fibroblasts were activated in UC inflammation. Conclusion Our study found a new cell type, the DUOX2+ enterocyte that is primarily present in inflamed conditions, and based on their expression profile, potentially perform antigen presentation. Moreover, we highlight that PSC-IBD, but not UC, is characterized by the activation of inflammatory HLA-DRB1+ monocytes, which are likely involved in the activation of CD4+ T cells. Notably, we observed an increased abundance of stem cells in non-inflamed PSC-IBD, possibly linked to the elevated risk of colorectal cancer in PSC-IBD. What is known on the subject?Inflammatory Bowel Disease (IBD) presents in 60–80% of primary sclerosis cholangitis (PSC) patients, termed PSC-IBD. However, the clinical presentation is distinct: patients have 10 times increased risk of colorectal carcinoma as compared to ulcerative colitis (UC) patients, and the conventional IBD treatment regimen is not always effective. The underlying genetic predisposition is also different from general IBD, where PSC-IBD shows a very strong risk association in the HLA-DRB1 region, generally a hallmark of auto-immune disease. What this study adds This study uncovers that PSC-IBD has more autoimmune and UC more inflammatory characteristics. This is supported by the interaction between inflammatory monocytes and CD4+/CD8+ T cells through HLA-DR in PSC-IBD. PSC-IBD patients have pronounced increased activity of inflammatory monocytes, not seen in UC. We find increased stem cell abundance in PSC-IBD. In addition, we show cellular-molecular mechanisms potentially driving the increased risk of carcinoma in PSC-IBD patients offering valuable foundations for targeted therapeutic strategies. In addition, we determined the new DUOX2+ enterocyte. How this research might affect research, practice, or policy This study uncovers that PSC-IBD has more autoimmune characteristics whereas UC is an immune mediated inflammatory disease. This is supported by the specific interaction between inflammatory monocytes and CD4+/CD8+ T cells through HLA-DR in PSC-IBD, while in UC DUOX2+ enterocytes and inflammatory monocytes communicate with innate immune cells, Tregs and CD4+ T cells. Our findings may form new treatment targets for PSC-IBD and IBD in general.
Open AccessInflammatory Bowel Disease in patients with Primary Sclerosing Cholangitis: a distinct form of colitis
Background and aims Primary sclerosing cholangitis (PSC) is an inflammatory disorder of the bile ducts, often accompanied by inflammatory bowel disease (PSC-IBD). Substantial differences in clinical presentation are observed between PSC-IBD and ulcerative colitis (UC). In this study we aim to find distinct pathomechanisms for PSC-IBD using single-cell mRNA sequencing. Methods Forty-seven colonic mucosal biopsies of PSC-IBD (n=24), UC (n=18) (where possible matched inflamed (I) non-inflamed (NI)), and non-IBD subjects (n=5) were collected and dissociated. Library preparation and processing for sequencing was followed by differential abundance, differential expression, and cell-cell-interaction analyses. Stainings for DUOX2 and HLA-DR were applied on tissue sections. Results In total, 71,798 cells comprised 54 distinct cell types, including a new cell type: the DUOX2+ enterocyte, mainly present in inflamed colon and acting as antigen presenting cells (HLA-DR+). Stem cells exhibited increased abundances in PSC-NI but not in UC-NI. Additionally, we found distinct gene expression profiles in PSC and UC which were related to inflammation: while mainly inflammatory monocytes were activated in PSC inflammation, and inflammatory fibroblasts were activated in UC inflammation. Conclusion Our study found a new cell type, the DUOX2+ enterocyte that is primarily present in inflamed conditions, and based on their expression profile, potentially perform antigen presentation. Moreover, we highlight that PSC-IBD, but not UC, is characterized by the activation of inflammatory HLA-DRB1+ monocytes, which are likely involved in the activation of CD4+ T cells. Notably, we observed an increased abundance of stem cells in non-inflamed PSC-IBD, possibly linked to the elevated risk of colorectal cancer in PSC-IBD. What is known on the subject?Inflammatory Bowel Disease (IBD) presents in 60–80% of primary sclerosis cholangitis (PSC) patients, termed PSC-IBD. However, the clinical presentation is distinct: patients have 10 times increased risk of colorectal carcinoma as compared to ulcerative colitis (UC) patients, and the conventional IBD treatment regimen is not always effective. The underlying genetic predisposition is also different from general IBD, where PSC-IBD shows a very strong risk association in the HLA-DRB1 region, generally a hallmark of auto-immune disease. What this study adds This study uncovers that PSC-IBD has more autoimmune and UC more inflammatory characteristics. This is supported by the interaction between inflammatory monocytes and CD4+/CD8+ T cells through HLA-DR in PSC-IBD. PSC-IBD patients have pronounced increased activity of inflammatory monocytes, not seen in UC. We find increased stem cell abundance in PSC-IBD. In addition, we show cellular-molecular mechanisms potentially driving the increased risk of carcinoma in PSC-IBD patients offering valuable foundations for targeted therapeutic strategies. In addition, we determined the new DUOX2+ enterocyte. How this research might affect research, practice, or policy This study uncovers that PSC-IBD has more autoimmune characteristics whereas UC is an immune mediated inflammatory disease. This is supported by the specific interaction between inflammatory monocytes and CD4+/CD8+ T cells through HLA-DR in PSC-IBD, while in UC DUOX2+ enterocytes and inflammatory monocytes communicate with innate immune cells, Tregs and CD4+ T cells. Our findings may form new treatment targets for PSC-IBD and IBD in general.
- Open Access
- 1 April 2024
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 51 (7) , 687-695
Increased Interferon Signaling in Vaginal Tissue of Patients With Primary Sjögren Syndrome
Objective: Vaginal dryness is an important factor influencing sexual function in women with primary Sjögren syndrome (pSS). Previous studies showed a higher degree of inflammation in vaginal biopsies from patients with pSS compared to non-pSS controls. However, the molecular pathways that drive this inflammation remain unclear. Therefore, the aim of this study was to investigate inflammatory pathway activity in the vaginal tissue of patients with pSS.Methods: Vaginal biopsies of 8 premenopausal patients with pSS experiencing vaginal dryness and 7 age-matched non-pSS controls were included. Expression of genes involved in inflammation and tissue homeostasis was measured using NanoString technology and validated using TaqMan Real-Time PCR. Vaginal tissue sections were stained by immunohistochemistry for myxovirus resistance protein 1 (MxA) and CD123 (plasmacytoid dendritic cells [pDCs]).Results: The most enriched pathway in vaginal biopsies from patients with pSS compared to non-pSS controls was the interferon (IFN) signaling pathway (P< 0.01). Pathway scores for Janus kinase and signal transducer and activator of transcription (JAK-STAT) and Notch signaling were also higher (P< 0.01 for both pathways). Conversely, transforming growth factor-β signaling and angiogenesis pathway scores were lower in pSS (P= 0.02 andP= 0.04, respectively). Differences in IFN signaling between patients with pSS and non-pSS controls were confirmed by PCR and MxA tissue staining. No CD123+ pDCs were detected in vaginal biopsies. IFN-stimulated gene expression levels correlated positively with CD45+ cell numbers in vaginal biopsies and serum anti-SSA/Ro positivity.Conclusion: Upregulation of IFN signaling in vaginal tissue of women with pSS, along with its association with tissue pathology, suggests that IFNs contribute to inflammation of the vaginal wall and potentially also to clinical symptomatology (ie, vaginal dryness).
- 1 April 2024
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 51 (7) , 687-695
Open AccessIncreased Interferon Signaling in Vaginal Tissue of Patients With Primary Sjögren Syndrome
Objective: Vaginal dryness is an important factor influencing sexual function in women with primary Sjögren syndrome (pSS). Previous studies showed a higher degree of inflammation in vaginal biopsies from patients with pSS compared to non-pSS controls. However, the molecular pathways that drive this inflammation remain unclear. Therefore, the aim of this study was to investigate inflammatory pathway activity in the vaginal tissue of patients with pSS.Methods: Vaginal biopsies of 8 premenopausal patients with pSS experiencing vaginal dryness and 7 age-matched non-pSS controls were included. Expression of genes involved in inflammation and tissue homeostasis was measured using NanoString technology and validated using TaqMan Real-Time PCR. Vaginal tissue sections were stained by immunohistochemistry for myxovirus resistance protein 1 (MxA) and CD123 (plasmacytoid dendritic cells [pDCs]).Results: The most enriched pathway in vaginal biopsies from patients with pSS compared to non-pSS controls was the interferon (IFN) signaling pathway (P< 0.01). Pathway scores for Janus kinase and signal transducer and activator of transcription (JAK-STAT) and Notch signaling were also higher (P< 0.01 for both pathways). Conversely, transforming growth factor-β signaling and angiogenesis pathway scores were lower in pSS (P= 0.02 andP= 0.04, respectively). Differences in IFN signaling between patients with pSS and non-pSS controls were confirmed by PCR and MxA tissue staining. No CD123+ pDCs were detected in vaginal biopsies. IFN-stimulated gene expression levels correlated positively with CD45+ cell numbers in vaginal biopsies and serum anti-SSA/Ro positivity.Conclusion: Upregulation of IFN signaling in vaginal tissue of women with pSS, along with its association with tissue pathology, suggests that IFNs contribute to inflammation of the vaginal wall and potentially also to clinical symptomatology (ie, vaginal dryness).